Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TUB-040
TUB-040 · 4 trials · 5 indications
Incidence and severity of treatment-emergent adverse events (TEAEs)
Assessment of overall response rate (ORR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1 as assessed by the investigator (INV)
Incidence and severity of treatment-emergent adverse events (TEAEs)
Incidence of dose-limiting toxicities (DLTs) at each dose level
Investigator (INV) assessment of overall response rate (ORR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1
Occurrence and severity of treatment-emergent adverse events (TEAEs)
Occurrence of DLTs (Dose limiting toxicities) at different dose levels (during first treatment cycle)
ORR is defined as the percentage of participants who have achieved complete response (CR) or partial response (PR), as assessed by BICR.
| Arm | Type | Description |
|---|---|---|
| NSCLC Dose 1 | EXPERIMENTAL | Participants will receive TUB-040 administered as an intravenous (IV) infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent. |
| NSCLC Dose 2 | EXPERIMENTAL | Participants will receive TUB-040 administered as an IV infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent. |
| Phase 1: Dose Escalation of TUB-040 | EXPERIMENTAL | Participants will receive escalating doses of TUB-040 to determine recommended Phase 2 dose (RP2D). |
| Phase 2: Monotherapy of TUB-040 | EXPERIMENTAL | Participants in Phase 2 will receive the recommended dose of TUB-040 monotherapy determined in Phase |
| Phase 1b Dose Escalation | EXPERIMENTAL | Drug TUB-040 administered in combination with carboplatin (Carbo) and bevacizumab (BEV) |
| Phase 1: Cohort 1: Dose Escalation in Platinum Resistant Ovarian Cancer (PROC) | EXPERIMENTAL | Participants will receive escalating doses of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects. |
| Phase 1: Cohort 2: Dose Escalation in R/R NSCLC of the adenocarcinoma subtype | EXPERIMENTAL | Participants will receive escalating doses of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects. |
| Phase 1: Cohort 3: PROC, Combination with Bevacizumab (BEV) | EXPERIMENTAL | Participants will receive escalating doses of TUB-040 combined with BEV every 3 weeks until the disease progresses or the patient has to stop due to side effects. |
| Phase 2a: Dose Optimization in PROC | EXPERIMENTAL | Participants will receive two different dose levels of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects. |
| Phase 2b: Dose Expansion in PROC | EXPERIMENTAL | Patients will receive TUB-040 at the safe dose established during dose escalation until disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| TUB-040 | DRUG | Administered IV |
| TUB-040 - Dose escalation | DRUG | TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle. |
| TUB-040 - RP2D | DRUG | TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle. Dose based on the RP2D |
| TUB-040 + Carbo + BEV | DRUG | Ph1b: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles. |
| Bevacizumab | DRUG | Administered IV |
Key Inclusion Criteria: 1. Adults, male or nonpregnant, nonbreastfeeding female, age ≥18 years at the date of consent. 2. Eastern Cooperative Oncology Group performance status of 0 or 1. 3. Documented radiographic progression on or after the most recent line of anticancer therapy. 4. Life expectanc...
TUB-040 is an investigational oncology therapy being studied in non-small cell lung cancer, ovarian cancer, and uterine endometrial cancer. It is given alone or in combination with standard chemotherapy and bevacizumab, depending on the tumor type and trial. It is not approved for any use and remains in clinical development.
TUB-040 targets NaPi2b, a protein target. It is described as a NaPi2b antibody-drug conjugate, meaning the therapy is directed at NaPi2b-expressing cells. The trials enroll patients with nonsquamous NSCLC, ovarian cancer, and uterine endometrial cancer without a stated biomarker selection requirement.
TUB-040 is being developed by Gilead Sciences, Inc., which trades on Nasdaq under the ticker GILD. The company is running the clinical program across lung, ovarian, and uterine cancer indications in the United States and several European sites.
TUB-040 is in Phase 2 clinical development. The program includes Phase 1/Phase 2 studies and a dedicated Phase 2 study in nonsquamous non-small cell lung cancer. TUB-040 is investigational and has not been approved by the FDA for any indication.
TUB-040 is studied in NCT06303505, a first-in-human Phase 1/Phase 2 trial in ovarian cancer and NSCLC that is recruiting, and NCT07736937, a Phase 1/Phase 2 ovarian cancer combination study that is recruiting. Two further studies, NCT07806773 in NSCLC and NCT07743541 in uterine cancer, are not yet recruiting.